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ConjugationofsiRNAtomacromoleculessuchasserumalbuminhasmultiplepotentialbeneﬁts,includingenhancedextravasation
via albumin-mediated transcytosis across endothelial cells and reduced renal clearance. In attempting to conjugate siRNA to
albumin, we used commercially sourced amine-modiﬁed siRNA and reacted it with the heterobifunctional linker succinimidyl
4-[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC) to introduce a maleimide group suitable for conjugation to the thiol
group of the surface-exposed cysteine residue (Cys 34) within albumin. We found the conjugation of the SMCC-treated siRNA to
bovine serum albumin (BSA) to be very ineﬃcient and investigated the cause of the low yield of conjugate. Ultraﬁltration with
phosphate-buﬀered saline prior to activation with SMCC dramatically increased the yield of siRNA-albumin conjugate (∼15-
fold).Communicationwiththe commercialsupplier revealed thatammoniumacetate buﬀer was used ina desaltingstep aspart of
the siRNA puriﬁcation process prior to supply, likely resulting in ammonium counterions to the siRNA polyanion, which would
interfere with conjugation by consuming the SMCC. After ultraﬁltration, a greatly reduced amount of SMCC could be used to
aﬀect conjugation, without signiﬁcant reduction in yield. These data indicate that amine-modiﬁed siRNA sourced commercially
may require ultraﬁltration or dialysis prior to use in conjugation reactions.
1.Introduction
A series of obstacles impede the successful delivery of
short interfering RNA (siRNA) to the cytosol of target cells
[1, 2]. Strategies involving conjugation of siRNA to a wide
variety of molecules have been employed to overcome these
obstacles. Typically, these approaches employ amine- [3]o r
thiol-modiﬁed [4, 5]s i R N Aa t3   or 5  ends of one strand
of the siRNA duplex (see [6] for review of conjugation
chemistry). Conjugations of siRNA to polyethylene glycol
[5], quantum dots containing targeting moieties [4], cell
penetrating peptides such as penetratin [7], and a range of
lipophilic molecules, including cholesterol [8], have been
demonstrated without a loss of silencing ability.
Recently, we embarked on a project aiming to deliver
siRNA to the heart using siRNA conjugated to the serum
protein albumin. The strategy employed involved the use
of the common heterobifunctional linker succinimidyl 4-
[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC).
Using this approach, the coupling of SMCC to siRNA
containing an aminohexyl pendant at the 3  end of the sense
strandresultsinan“activated”siRNAbearingathiol-reactive
maleimide group. The “activated” siRNA is then covalently
linked to serum albumin via reaction with the thiol-
containing side chain of cysteine residue 34, located on the
surface of serum albumin molecules (see Figure 1). Previous
studies have shown that a number of thiol-reactive drugs
rapidly and selectively bind to endogenous albumin within a
few minutes of administration, due to that fact that free thiol
groups are not found on the majority of circulating serum
proteins except for albumin [9]. The chemistry used to con-
jugate the siRNA to albumin is not novel; others have con-
jugated nanoparticles to siRNA using a similar cross-linker,
N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP)[10].2 Journal of Nucleic Acids
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Figure 1: Conjugation chemistry. Formation of an amide bond between the heterobifunctional cross-linker SMCC and commercially
sourced amine-modiﬁed siRNA produces maleimide-functionalized siRNA (activated siRNA). The activated siRNA reacts with cysteine-
34 of BSA to produce an siRNA-BSA conjugate.
These workers employed a 40:1 SPDP:siRNA ratio to
activate the siRNA and then gel ﬁltration to remove the
unreacted SPDP, prior to conjugation. We found signiﬁcant
batch-to-batch variability in the eﬃciency of the siRNA con-
jugation to bovine serum albumin (BSA) using similar con-
ditions and therefore sought to understand the factors lim-
iting the conjugation. Here, we report a successful strategy
torestore conjugation eﬃciency,by repeated buﬀerexchange
prior to exposing the amine-modiﬁed siRNA to SMCC.
2.ExperimentalMethods
2.1. Materials. Samples of IGF-IR siRNA used were sourced
from Dharmacon (CO, USA) and were modiﬁed with an
amine for conjugation, with 2 -O-methyl modiﬁcations
for in vivo use, and with a ﬂuorescein label for imaging
purposes. Each sense strand contained four 2 -O-methyl
modiﬁcations, whilst the antisense strand contained two 2 -
O-methyl modiﬁed nucleotides. The sense strand contained
a3   amine modiﬁcation (N6) and a ﬂuorescein label (Fl) at
its5  end.Thesequenceusedwasasfollows,where “m”refers
to 2 -O-methyl modiﬁcation:
sense strand: 5 -Fl(∗)GCmCmCAUmGUGUGAGAm-
AGACC(∗)dT(∗)dT(∗)N6-3 ,
antisense strand: 3 -dT(∗)dT(∗)CGGGUACACACm-
UCUUCUmGG-5 .
(∗) denotes phosphorothioate linkages.
The siRNA was dissolved in freshly prepared phosphate-
buﬀeredsaline (PBS,pH 7.4)or 250mM borate buﬀer(pH 8
or 8.5) to a concentration of 0.2mM and stored at −20◦C
prior to use. BSA used was bovine serum albumin (BSA,
Grade V Sigma USA). 4-[N-maleimidomethyl]cyclohexane-
1-carboxylate (SMCC) was purchased from Pierce Chemical
CO (CA, USA)and dissolved in DMSO (9.57mM) just prior
to use.
2.2. Reaction Conditions for Conjugation without Ultraﬁltra-
tion Step. siRNA-BSA covalent conjugates were formed by
reacting the 3 -amine-modiﬁed, ﬂuorescein-labeled siRNA
with the heterobifunctional linker reagent SMCC to form
an irreversible amide linkage (see Figure 1). Aliquots of
siRNA and SMCC linker were combined to give a ratio of
1 n m o ls i R N A( 0 . 2 n M )t o4 0 n m o lS M C C( 9 . 5 8 n M )i na
∼1:1 mixture of MilliQ water and DMSO and allowed to
react for 1h at room temperature. Excess SMCC was then
removed by gel ﬁltration chromatography using a NAP-5
column (Pharmacia, UK), with only the ﬂuorescent ﬂow-
through collected. The quantity of siRNA collected was then
determined by ﬂuorescence using an EnVision Multilabel
Plate Reader (USA) with 488nm excitation/520nm emis-
sion. The activated siRNA was then coupled to the surface-
exposed cysteine of BSA by incubating the siRNA with 2
molar equivalentsofBSAfortime periodsofupto 24h (ﬁnal
concentrations of siRNA and BSA in the reaction mixture
were 30.3 and 60.6μM, resp.).
The components present in the reaction mixture were
examined on a 10% SDS-PAGE, together with BSA and
siRNA standards of known molecular weight (66.5 and
14kDa, resp.). The gels were loaded with 1μgp r o t e i np e r
well and run for 90min at a constant voltage of 100V in
SDS running buﬀer. siRNA was visualized under UV light or
using Typhoon gel scanner for detection of ﬂuorescein emis-
sion at 520nm, and BSA was visualised following Coomassie
Brilliant Blue staining. Quantitation of the relative amounts
of conjugate and unreacted siRNA was performed by den-
sitometric analysis of siRNA and BSA bands recorded on gel
scans.Journal of Nucleic Acids 3
2.3. Reaction Conditions for Conjugation with Ultraﬁltration
Step. Prior to conjugation, the reconstituted IGF-IR siRNA
was subjected to four rounds of ultraﬁltration with PBS
buﬀe ru s i n ga nA m i c o nU l t r a - 4c e n t r i f u g a l3k D aﬁ l t e ru n i t
spun at 4000rpm for 50min at 4◦C after each addition of
fresh buﬀer. The concentrated siRNA was removed from the
ﬁlter unit and quantiﬁed on an EnVision Multilabel Plate
Reader(USA).Conjugationwasthenperformedasdescribed
above.
3.Resultsand Discussion
As documentation supplied with the commercially supplied
amine-modiﬁed siRNA did not contain any information to
suggest the contrary, it was presumed that the siRNA would
be suitable for conjugation to amine-reactive compounds
after simply reconstituting in an appropriate buﬀer. How-
ever, initial attempts to couple the siRNA to BSA via the
use of SMCC, a heterobifunctional cross-linker routinely
employed to link amine- to thiol-bearing molecules, met
with very limited success. Following the literature precedent,
siRNA was reacted (activated) with a 40-fold molar excess of
SMCC prior to exposure to BSA, as described in Section 2,
and at the completion of the reaction samples were analysed
via PAGE. Figure 2(a) shows a representative PAGE gel, used
to evaluate conjugation eﬃciency; scanning under 488nm
excitation reveals siRNA standard at 14kDa in lane 3, with
lanes 4 and 5 showing a signiﬁcant band corresponding to
unreacted siRNA band and a faint band at the size expected
f o rt h es i R N A - B S Ac o n j u g a t e ,a p p r o x i m a t e l y8 0K D a .D e n -
sitometric analysis indicated that only 4-5% of siRNA was
conjugated to BSA and that there was no diﬀerence in yield
between a one-hour and three-hour activation time. Whilst
there was some batch-to-batch variability, the majority
of conjugation reactions performed using several separate
batchesofamine-modiﬁed siRNAgavesimilarlypoorresults,
with less than 20% of siRNA in conjugate form. Figure 2(b)
shows the same PAGE gel that is shown in Figure 2(a),
in this case after Coomassie (protein) staining to reveal
BSA. As expected, the BSA standard ran at 66kDa. There
was no clear band apparent at 80kDa, likely indicating
that the small amount of siRNA-BSA conjugate evident in
Figure 2(a)was belowthe limit ofdetection using Coomassie
staining.
In troubleshooting the ineﬃcient conjugation reaction,
a range of experimental parameters were varied in an
attempttodrivethereactiontocompletion.Thereactionwas
performed overnight, at pH values between 7 and 8.5, and
using a range of siRNA, SMCC, and BSA concentrations and
molar ratios. None of these strategies were successful (data
not shown). Finally, we hypothesized that there may have
been low-molecular-weight species in the siRNA as supplied
that interfered with the conjugation reaction and, therefore,
that extensive ultraﬁltration or dialysis prior to activation
with SMCC to remove these species might improve the
outcome of the conjugation reaction. Communication with
the manufacturer revealed that the siRNA was desalted using
ammonium acetate; an unwise choice for amine-modiﬁed
SMCC activation time
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Figure 2: Ineﬃcient conjugation using amine-modiﬁed siRNA
without prior ultraﬁltration to remove ammonium counterions.
SDS-polyacrylamide gel showing outcome of siRNA-BSA conjuga-
tion reaction using 1- and 3-hour SMCC activation times. Amine-
modiﬁed siRNA was activated with SMCC in a molar ratio of
40:1 for 1 or 3h, followed by conjugation with BSA over 24h. (a)
Faint bands at the predicted conjugate size were observed under
excitation with 488nm light, with the majorityof siRNA unreacted.
(b) Only a single unconjugated albumin band was revealed by
Coomassie Brilliant Blue staining in each case. siRNA std:siRNA
standard; BSA std:BSA standard.
siRNA whose likely purpose is conjugation via the amine
functional group, since ammonium ions would become
counterions to the polyanionic siRNA. In solution, there
is an equilibrium between ammonium ions and ammonia.
Ammonia can act as a nucleophile, similar to the primary
amine in the modiﬁed siRNA, and hence is also able
to react with the succinimidyl ester group in the SMCC
linker.
Figure 3(a) (i) shows the reaction products before (lane
4) and after (lane 5) four rounds of ultraﬁltration with
PBS. Ultraﬁltration prior to SMCC activation resulted in a
15-fold increase in the proportion of siRNA converted to
the conjugate form, as evidenced by the band at 80kDa.
After Coomassie staining of this gel, a clear band at 80kDa
was evident in addition to the native BSA band, indicating
the BSA component of the conjugate (Figure 3(a) (ii)).
Densitometric analysis of the unreacted and conjugate BSA
bands indicated that approximately one third of the BSA
was involved in the reaction. This is not unexpected given
that approximately 70% of albumin is in the thiol reactive
(mercaptalbumin)form[11]andthat a2:1albumin:siRNA
ratio was employed. Thus, it appears that removal of the
ammonium counterions from the amine-modiﬁed siRNA
prevents the majority of the SMCC from being consumed
by a competitive side reaction, and thus it allows the
reaction of siRNA with SMCC to proceed more eﬀec-
tively.
Having demonstrated that the reaction eﬃciency was
dramatically improvedby ultraﬁltrationusing PBS,weantic-
ipated that the ratio of SMCC linker to siRNA used (40:1)4 Journal of Nucleic Acids
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Figure 3: Ultraﬁltration dramatically increases siRNA-albumin
conjugate yield. (a) SDS-polyacrylamide gel showing outcome of
siRNA-BSA conjugation reaction without prior ultraﬁltration (lane
4) and subsequent to ultraﬁltration of siRNA (lane 5). A 15-fold
increaseinconjugatebandintensitywasobservedusingultraﬁltered
siRNA, compared to amine-modiﬁed siRNA simply reconstituted
in buﬀer, when scanned at 488nm. A visible band at the predicted
conjugate size was also apparent after staining with Coomassie
Brilliant Blue. (b) siRNA conjugation was eﬃcient after buﬀer
exchange with either PBS (pH 7.4) or borate buﬀer (pH 8). siRNA
std:siRNA standard; BSA std:BSA standard.
was unnecessarily high. Figure 4 shows evaluation of the
eﬀect of reducing the SMCC:siRNA ratio on the outcome
of the conjugation reaction. There was no reduction in
the proportion of siRNA in conjugate form upon reducing
the SMCC:siRNA ratio from 40:1 to 10:1, and only
a modest decrease occurred when the ratio was further
reduced to 2:1 (48% of siRNA in conjugate form versus
61% for 40:1 ratio, Figure 4(a)). Thus, it was possible to
reduce the SMCC concentration during the reaction, with
the advantage of reducing the amount of excess linker
remaining after the reaction, as well as lowering the cost of
synthesis.
4.Conclusions
These data clearly demonstrate that siRNA supplied com-
mercially with terminal amine groups can require ultraﬁltra-
tion or dialysis prior to exposure to linker reagents in order
to remove ammonium ions remaining after the desalting
step used in the puriﬁcation process. Researchers planning
to perform conjugation experiments should consult with the
supplier as to the puriﬁcation conditions, and if it is known
or suspected that ammonium-containing salts were used, an
ultraﬁltration step, as described herein, should be performed
prior to use of the siRNA.
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Figure 4: SMCC:siRNA ratio can be reduced without loss of
yield after ultraﬁltration of amine-modiﬁed siRNA. Conjugation
of amine-modiﬁed siRNA with BSA using 40:1, 10:1, and 2:1
SMCC-to-siRNA molar ratios. Conjugates formation was observed
for each of the SMCC:siRNA ratios; reducing the ratio from
40:1 to 2:1 had relatively little eﬀect on conjugate yield. siRNA
std:siRNA standard; BSA std:BSA standard.
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